Revenue
2012
2012
2013
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Xenetic Biosciences, Inc. (XBIO)
Price$4.67Cached quote
Net income
2012
2012
2013
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2012
2013
2013
2014
2015
2016
2017
2018
2022
Total cash / debt
CashTotal debt
2012
2012
2013
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 · Dec 31 | 2013 · Aug 31 | 2012 · Dec 31 | 2012 · Aug 31 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $2.5M | $2.5M | $1.7M | $1.2M | $436,942 | $17,066 | $0 | $7.6M | $3.0M | $0 | $0 | $1.0M | $96,900 | $293,603 | $112,786 |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | $0 | $1.0M | — | $248,765 | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — | 100.00% | — | 84.73% | — |
| Research & development | $3.1M | $3.3M | $3.5M | $4.8M | $3.2M | $1.7M | $4.9M | $2.9M | $4.1M | $43.7M | $3.4M | $6.3M | $3.1M | — | $1.9M | — |
| Operating expenses | $5.8M | $6.7M | $7.1M | $8.4M | $6.9M | $14.4M | $12.9M | $7.3M | — | — | — | $12.9M | $9.6M | $162,457 | $6.6M | $229,447 |
| Operating income | −$2.8M | −$4.2M | −$4.5M | −$6.7M | −$5.7M | −$13.9M | −$12.9M | −$7.3M | −$3.6M | −$47.4M | −$9.8M | −$12.9M | −$8.6M | −$65,557 | −$6.3M | −$116,661 |
| Operating margin | −95.23% | −168.16% | −177.79% | −393.57% | −495.12% | −3,189.82% | −75,511.71% | — | −47.05% | −1,581.02% | — | — | −861.35% | −67.65% | −2,160.83% | −103.44% |
| EBITDA | −$2.8M | −$4.2M | −$4.5M | −$6.7M | −$5.7M | −$13.9M | −$12.9M | −$7.3M | −$3.5M | −$47.4M | −$9.8M | −$12.8M | −$8.6M | — | −$6.2M | −$97,180 |
| EBITDA margin | −95.23% | −168.16% | −177.79% | −393.57% | −495.12% | −3,189.59% | −75,487.11% | — | −46.74% | −1,579.81% | — | — | −856.14% | — | −2,125.20% | −86.16% |
| Net income | −$2.7M | −$4.0M | −$4.1M | −$6.6M | −$5.6M | −$10.9M | −$12.8M | −$7.3M | −$3.6M | −$54.2M | −$12.5M | −$14.3M | −$8.6M | −$89,172 | −$6.3M | −$89,172 |
| Net profit margin | −90.07% | −158.39% | −162.78% | −383.87% | −486.36% | −2,493.11% | −74,856.59% | — | −47.40% | −1,806.87% | — | — | −857.92% | −92.02% | −2,155.41% | −79.06% |
| Basic EPSper basic share | -$1.58 | -$2.57 | -$2.71 | -$4.61 | -$5.50 | -$17.00 | -$63.30 | -$96.60 | -$49.20 | -$940.80 | -$355.20 | -$435.60 | -$277.20 | $0.00 | -$198.00 | -$39.60 |
| Diluted EPSper diluted share | -$1.58 | -$2.57 | -$2.71 | -$4.61 | -$5.50 | -$17.00 | -$63.30 | -$96.60 | -$49.20 | -$940.80 | -$355.20 | -$435.60 | -$277.20 | $0.00 | -$198.00 | -$39.60 |
Owners
Reported shareholders
5.01%of listed shares
RENAISSANCE TECHNOLOGIES LLC117.44K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
RENAISSANCE TECHNOLOGIES LLC | 5.01%117.44K shares |
PARSLOW JAMES F | ≈4.27%100K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.74%17.42K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.54%12.68K shares |
JTC Employer Solutions Trustee Ltd | 0.12%2.7K shares |
SBI Securities Co., Ltd. | 0.04%1K shares |
Tower Research Capital LLC (TRC) | 0.03%696 shares |
MORGAN STANLEY | <0.01%150 shares |
Darwin Wealth Management, LLC | <0.01%2 shares |
Percentages use 2.34M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data